PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
10504298-8	1999	To determine if K5-PKCalpha mice display an altered response to TPA-promotion, 7, 12-dimethylbenz[a]anthracene-initiated K5-PKCalpha mice and wild-type mice were promoted with TPA.	anthracene	100-110	protein kinase C, alpha	Mus musculus	124-132	
22843879-0	2012	PKCalpha suppresses 7,12-dimethylbenz[a]anthracene-induced skin tumor formation.	anthracene	40-50	protein kinase C, alpha	Mus musculus	0-8	
8242857-4	1993	A characteristic of 7,12-dimethylbenz[a]anthracene (DMBA)-initiated papillomas, which contain an A-->T mutation in the 61st codon of Ha-ras, is that they exhibit a constitutive decrease in both protein kinase C (PKC) activity and PKC alpha and beta 2 isozyme levels when compared to epidermis.	anthracene	40-50	protein kinase C, alpha	Mus musculus	233-242	
16103087-2	2005	PKCalpha-deficient mice exhibited increased susceptibility to tumor formation in two-stage skin carcinogenesis by single application of 7,12-dimethylbenz(a)anthracene (DMBA) for tumor initiation and repeated applications of 12-O-tetradecanoylphorbol-13-acetate (TPA) for tumor promotion.	anthracene	156-166	protein kinase C, alpha	Mus musculus	0-8	
19118017-3	2009	Furthermore, when K5-PKCalpha mice were initiated with 7,12-dimethylbenz(a)anthracene (DMBA) and promoted with a low dose of TPA, 58% of K5-PKCalpha mice developed skin papillomas that progressed to carcinoma, whereas wild-type mice did not develop tumors.	anthracene	75-85	protein kinase C, alpha	Mus musculus	21-29